moneyheap
ALNY +5.36% today · Analysis updated Nov 13, 2026, 4:46 PM ET
Why is Alnylam Pharmaceuticals, Inc. (ALNY) stock up today?
ALNY is trading near $165 on Nov 13 (high $168.33), up about 5% from the $156.65 close on Nov 12. Volume is about 3.6M shares, in line with recent days. The stock is still about 29% below its $232.40 close on Oct 28. It fell 25% on Oct 29 on 11.8M shares after Q3 results, when slowing US Amvuttra growth and a weaker outlook overshadowed in-line revenue. Truist and Bernstein downgraded the stock, and analysts including Citi, Goldman and UBS cut targets, though most remain at Buy. The company has since announced a $1B buyback, with about $500M planned by year-end. It reiterated 2026 net product revenue guidance of $4.7B-$5.1B and presented positive five-year HELIOS-B data. The stock closed at a one-year low of $151.64 on Nov 10, then rebounded on Nov 11 and again on Nov 13. It remains below its key moving averages. Upcoming ISA posters on Nov 16-18 include a comparison with acoramidis. The Chief Commercialization Officer is leaving, and the next hard test is Q4 results and 2027 guidance in February 2027. The rebound is encouraging but not yet a confirmed trend change.
News behind the analysis
- What Moved Alnylam Stock?The stock rose 5.4% on Nov 11 after closing at $151.64 on Nov 10, its lowest close in a year. The company reported no earnings that day. Q4 results and 2027 guidance are expected in February 2027.
- Alnylam Pharmaceuticals (ALNY) Is Up 5.4% What's Changed After Five Year Drug DataFive-year HELIOS-B data showed lower all-cause mortality and fewer recurrent cardiovascular events. About $500M of the $1B buyback is planned by year-end.
- Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA in ATTR-CMThe AHA data showed sustained benefit over 60 months across mortality, cardiovascular events and quality of life, with a consistent safety profile.
- Alnylam shares jump around 5.5% as strong Q3 product revenue drives commercial momentumThe stock rose 5.4% to $165.34 but remains below its 20-, 50- and 200-day moving averages.
- Truist Downgrades Alnylam Amid Amvuttra Sales ConcernsOn Nov 2, Truist cut the stock to Hold from Buy, citing lower Amvuttra sales forecasts.
- ALNY Stock Quote Price and ForecastCiti cut its target to $250 from $320 and kept Buy. The list also shows the Chief Commercialization Officer's departure and the $1B buyback.
- ALNY Stock Price, News & AnalysisThe Nov 4 buyback and commercial leadership change were announced. About $500M of buybacks are expected by end-2026, with more in 2027.
- Alnylam Pharmaceuticals (ALNY) Stock Price, Quote, News & AnalysisCoverage covers the Truist and Bernstein downgrades, the $1B buyback authorization, and Q3 results of $1.46B revenue.
- Alnylam to Present Five-Year HELIOS-B Data at AHA and ISA 2026ISA posters run Nov 16-18, including a matching-adjusted comparison of vutrisiran and acoramidis in ATTR-CM.
- Alnylam Pharmaceuticals Press ReleasesNov 10 release: Regeneron advanced CIDEB siRNA with promising first-in-human results in MASLD patients.
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a Cambridge, Massachusetts biotech that pioneered RNA interference (RNAi), a type of medicine that silences specific disease-causing genes. Its main drug, AMVUTTRA, treats ATTR amyloidosis, including the heart form (ATTR-CM). AMVUTTRA's ATTR-CM launch has turned Alnylam into a fast-growing commercial company with over $1 billion in quarterly product sales.
How it makes money
Most revenue comes from drug sales. The TTR franchise (AMVUTTRA plus the older drug ONPATTRO) brought in about $1.15 billion of roughly $1.46 billion in total Q3 2026 revenue, so around 80%. Two rare-disease drugs, GIVLAARI and OXLUMO, add roughly $140 million a quarter. Alnylam also earns royalties, mainly from Novartis's cholesterol drug Leqvio (about $95 million in Q3 2026), plus collaboration revenue from partners. Management's 2026 guidance is about $4.2–4.5 billion in TTR sales and about $4.7–5.1 billion in total product sales.
What usually moves ALNY
- AMVUTTRA uptake in ATTR cardiomyopathy
- Competition in ATTR from Pfizer's tafamidis and BridgeBio's acoramidis
- Quarterly sales vs. company guidance
- Pipeline trial readouts (e.g., nucresiran, Huntington's, hypertension)
- Drug pricing and Medicare reimbursement policy